BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
Jun 28, 2010
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Macugen pegaptanib: Phase III data

In the double-blind, international Phase III Study A5751013 trial in 260 patients, 0.3 mg intravitreal Macugen every 6 weeks met the primary endpoint of a significantly greater proportion of patients who gained >10 letters on the ETDRS eye chart from baseline to 1 year vs. sham control (37% vs. 20%, p=0.0047). Additionally, patients treated with Macugen gained an average of...

Read the full 278 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >